ID: h-348264d348
Hypothesis

Pericyte senescence is sufficient to weaken the BBB even without classic amyloid or tau proteinopathy

Selective induction of a senescence program in adult pericytes is sufficient to impair barrier-supportive trophic signaling, weaken endothelial tight-junction maintenance, and cause durable BBB leak that later contributes to neuronal dys.
🧬 CDKN2A, CDKN1A, IL6, CXCL8, TGFB1🩺 neurodegeneration🎯 Composite 63%💱 $0.57▼10.1%proposed
EvidencePending (0%)📖 7 cit🗣 1 debates 7 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.79 (15%) Evidence 0.61 (15%) Novelty 0.78 (12%) Feasibility 0.67 (12%) Impact 0.73 (12%) Druggability 0.44 (10%) Safety 0.41 (8%) Competition 0.74 (6%) Data Avail. 0.59 (5%) Reproducible 0.57 (5%) KG Connect 0.50 (8%) 0.630 composite

🧪 Overview

Selective induction of a senescence program in adult pericytes is sufficient to impair barrier-supportive trophic signaling, weaken endothelial tight-junction maintenance, and cause durable BBB leak that later contributes to neuronal dysfunction. This is a key causality hypothesis for deciding whether pericyte senescence is a primary lesion or mainly a reactive state.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Abeta/Tau Stress<br/>DNA Damage Signaling"]
    B["CDKN2A/p16 Upregulation<br/>INK4a Locus Activation"]
    C["CDK4/6 Inhibition<br/>Cyclin D Complex Blocked"]
    D["RB Hypophosphorylation<br/>Cell Cycle Arrest"]
    E["Cellular Senescence<br/>Permanent Growth Arrest"]
    F["SASP Secretion<br/>IL6/IL8/TNF/MMP Release"]
    G["Neuroinflammation<br/>Bystander Neuron Damage"]
    H["ARF/p19 Expression<br/>p53 Stabilization"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    B --> H
    H -.->|"amplifies"| E
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix7 supports2 contradicts
Supports
Senescent brain pericytes impair BBB integrity in vitro, directly linking pericyte senescence-like states to barrier dysfunction.
Supports
Vascular-cell senescence can impair BBB properties in vitro and in vivo, supporting senescence as a plausible upstream barrier lesion.
Supports
Tau protein aggregation is associated with cellular senescence in the brain.
Aging Cell2018PMID:30126037medium
Supports
Exposure to environmental airborne particulate matter caused wide-ranged transcriptional changes and accelerated Alzheimer's-related pathology: A mouse study.
Neurobiol Dis2023PMID:37739136medium
Supports
Gadd45A-mediated autophagy regulation and its impact on Alzheimer's disease pathogenesis: Deciphering the molecular Nexus.
Biochim Biophys Acta Mol Basis Dis2024PMID:39004381medium
Supports
Specific serum autoantibodies predict the development and progression of Alzheimer's disease with high accuracy.
Brain Behav Immun2024PMID:37989443medium
Supports
Astrocyte senescence may drive alterations in GFAPα, CDKN2A p14(ARF), and TAU3 transcript expression and contribute to cognitive decline.
Geroscience2019PMID:31654269medium
Contradicts
Current evidence is largely in vitro or accelerated-aging contexts and does not yet establish naturalistic pericyte-senescence-driven AD-like degeneration in vivo.
Contradicts
Artificial p16/p21 induction may create a nonphysiologic arrest state, so sufficiency tests risk overcalling endogenous senescence biology.
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — CDKN2A

No curated PDB or AlphaFold mapping for CDKN2A yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for CDKN2A, CDKN1A, IL6, CXCL8, TGFB1 from GTEx v10.

Spinal cord cervical c-10.9 Putamen basal ganglia0.8 Amygdala0.7 Cerebellum0.7 Frontal Cortex BA90.7 Caudate basal ganglia0.6 Cortex0.6 Hippocampus0.4 Anterior cingulate cortex BA240.4 Substantia nigra0.4 Cerebellar Hemisphere0.3 Nucleus accumbens basal ganglia0.3 Hypothalamus0.2median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for CDKN2A, CDKN1A, IL6, CXCL8, TGFB1 →

No DepMap CRISPR Chronos data found for CDKN2A, CDKN1A, IL6, CXCL8, TGFB1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.5%
Volatility
Low
0.0031
Events (7d)
2
Price History
▼10.1%

💾 Resource Usage

LLM Tokens
17,540
$0.0526
Total Cost
$0.0526

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF we selectively induce pericyte senescence in adult mice using pericyte-specific PDGFRβ-CreERT2 to drive CDKN2A overexpression (tamoxifen on P60-P75), THEN we will observe statistically significant ≥50% increase in brain parenchymal tracer accumulation in pericyte-senescent mice compared to controls— no observation —pending0.65
IF we pharmacologically prevent pericyte senescence in 5xFAD amyloid model mice by administering senolytic ABT-263 (navitoclax, 50mg/kg/day via drinking water) starting at 6 months, THEN we will obser≥40% reduction in IL6 and CXCL8 brain concentrations; ≥30% preservation of pericyte coverage; reversal of 5xFAD cognitive deficits to WT levels— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we selectively induce pericyte senescence in adult mice using pericyte-specific PDGFRβ-CreERT2 to drive CDKN2A overexpression (tamoxifen on P60-P75), THEN we will observe statistically significant increase in BBB permeability measured by extravasated Evan blue dye or 10kDa FITC-dextran fluorescen
Predicted outcome: ≥50% increase in brain parenchymal tracer accumulation in pericyte-senescent mice compared to controls
Falsification: No significant change in BBB permeability (p>0.05) or tracer accumulation unchanged relative to controls within 8 weeks
pendingconf 55%
IF we pharmacologically prevent pericyte senescence in 5xFAD amyloid model mice by administering senolytic ABT-263 (navitoclax, 50mg/kg/day via drinking water) starting at 6 months, THEN we will observe reduced brain IL6 and CXCL8 protein levels (by ELISA), preserved PDGFRβ+ pericyte coverage, and p
Predicted outcome: ≥40% reduction in IL6 and CXCL8 brain concentrations; ≥30% preservation of pericyte coverage; reversal of 5xFAD cognitive deficits to WT levels
Falsification: No reduction in inflammatory cytokines, persistent pericyte coverage loss, or continuing cognitive decline despite senolytic treatment; any of these would falsify pericyte senescence as necessary
Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.